Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease

Abstract

Aspirin-exacerbated respiratory disease (AERD) is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase-1 inhibitors.1 Patients with AERD have severe CRSwNP that is often refractory to standard therapies, including intranasal corticosteroids,2 and is associated with high utilization of health care resources.3 After endoscopic sinus surgery (ESS), nasal polyp regrowth occurs within 2 years for 85% of patients with AERD,4 and for many patients, surgery does not provide complete resolution of symptoms.